Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global rapid tests market size was valued at USD 10.72 billion in 2024. The market is projected to grow from USD 11.24 billion in 2025 to USD 14.74 billion by 2031, exhibiting a CAGR of 4.8% during the forecast period.
Rapid tests, also known as point-of-care tests (POCT), are diagnostic tools designed to deliver quick results without requiring specialized laboratory equipment. These tests utilize biological samples such as finger-prick blood or saliva, providing actionable results typically within 20-30 minutes at physician offices, clinics, or community settings. The technology bridges critical gaps in healthcare accessibility by enabling timely decision-making for disease management.
The market expansion is driven by growing demand for decentralized diagnostics, particularly for infectious diseases like COVID-19 and HIV, where WHO reports indicate approximately 40% of global diagnostics now utilize rapid testing formats. While affordability remains a key advantage, recent innovations in multiplex testing and digital connectivity are creating new growth avenues. Major players including Abbott, Roche Diagnostics, and Quidel dominate approximately 60% of the professional rapid test segment, with increasing competition from innovators developing smartphone-integrated testing solutions.
Increased Demand for Point-of-Care Testing
The rapid tests market is experiencing significant growth due to the rising demand for point-of-care diagnostics. Rapid tests provide quick results, often within minutes, making them ideal for emergency situations, home testing, and remote healthcare settings. The global adoption of rapid tests for infectious diseases like COVID-19, influenza, and sexually transmitted infections (STIs) has further fueled market expansion.
Technological Advancements in Diagnostics
Innovation in assay technologies, such as lateral flow assays and microfluidics, has enhanced the accuracy and efficiency of rapid tests. Companies are investing in developing multiplex rapid tests capable of detecting multiple pathogens simultaneously, significantly improving diagnostic capabilities.
The global rapid test market is projected to grow at a CAGR of 5.8% between 2023 and 2028, driven by increasing healthcare awareness and self-testing preferences.
Government initiatives and regulatory approvals for rapid diagnostic tests in both developed and developing nations are accelerating market penetration.
MARKET CHALLENGES
Regulatory and Accuracy Concerns
Despite their advantages, rapid tests face criticism over false positives and negatives, particularly in low-prevalence settings. Regulatory bodies impose strict validation requirements, and companies must continuously improve sensitivity and specificity to maintain compliance.
Other Challenges
Supply Chain and Raw Material Shortages
The rapid test manufacturing process relies on specialized components, and disruptions in supply chains can delay production. Additionally, competition for raw materials, such as nitrocellulose membranes used in lateral flow assays, may raise costs.
High Competition from Laboratory-Based Tests
Traditional laboratory-based diagnostic tests, such as PCR and ELISA, remain the gold standard for accuracy, limiting the adoption of rapid tests in clinical settings requiring definitive results. Healthcare providers often hesitate to replace conventional methods unless rapid tests achieve comparable precision.
Expansion in Emerging Markets
Emerging economies present untapped potential due to increasing healthcare expenditure and a growing need for affordable diagnostics. Rapid tests are particularly advantageous in regions with limited healthcare infrastructure, offering a cost-effective solution for disease screening and monitoring.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Professional Rapid Test Products dominate due to their clinical accuracy and widespread adoption in healthcare settings. These tests are typically administered by trained professionals and offer higher reliability. The OTC segment is gaining traction among health-conscious consumers seeking convenience for home monitoring of basic conditions. |
| By Application |
|
Infectious Disease testing remains the largest application segment, driven by pandemic preparedness and the need for quick diagnosis of conditions like influenza and HIV. Pregnancy and Fertility tests show strong consumer uptake due to their private and immediate results, while Glucose Monitoring maintains steady demand from diabetic populations. |
| By End User |
|
Hospitals and Clinics represent the primary end users, where rapid tests are critical for initial patient screening. Diagnostic Centers are increasingly adopting these tests to expand their service offerings, while Home Care Settings are witnessing accelerated growth due to rising preference for self-testing kits. |
| By Technology |
|
Lateral Flow Assays lead the technology segment due to their simplicity, portability, and cost-effectiveness. These disposable devices require minimal training to operate. The Agglutination Tests segment maintains relevance in specialized applications, while Flow-Through Tests are preferred for their higher throughput capabilities in clinical settings. |
| By Sample Type |
|
Blood-based tests remain predominant due to their analytical reliability for infectious disease and glucose monitoring. The Saliva segment is growing fastest as non-invasive sampling gains acceptance, especially in workplace and public health screening. Urine tests continue to be important for pregnancy and drug testing applications. |
Global Rapid Tests Market Dominated by Diagnostic Heavyweights and Specialized Providers
The rapid tests market is led by established diagnostic giants like Abbott and Roche Diagnostics, which hold significant market share through their extensive product portfolios and global distribution networks. The market structure remains moderately consolidated with the top 5 players accounting for over 45% of market revenue, while numerous specialized companies compete in niche segments such as infectious diseases, cardiology, and toxicology testing.
Emerging competitors like Quidel Corporation and OraSure Technologies are gaining traction through innovative rapid diagnostic solutions, particularly in point-of-care and over-the-counter testing segments. The market also features specialized players like Akers Biosciences and Meridian Bioscience focusing on specific testing applications, creating a diverse competitive environment with both global and regional participants.
List of Key Rapid Tests Companies ProfiledAkers Biosciences, Inc.
Bio-Rad Laboratories, Inc.
Hologic, Inc.
Meridian Bioscience, Inc.
Quidel Corporation
Siemens Healthineers
Thermo Fisher Scientific
Danaher Corporation
BioMrieux SA
Sekisui Diagnostics
The global rapid tests market is projected to grow from $10.7 billion in 2024 to $14.7 billion by 2031, with a CAGR of 4.8%. This growth is driven by increasing demand for point-of-care diagnostics that provide results within 20-30 minutes, eliminating the need for laboratory processing.
Other TrendsSegmentation by Test Type
The market is divided into Over-the-counter (57% market share) and Professional Rapid Test Products (43%). Increased consumer awareness and regulatory approvals for home testing kits are accelerating OTC segment growth.
Regional Market DevelopmentsNorth America currently holds 38% of the global market share, followed by Europe at 29%. The Asia-Pacific region is experiencing the fastest growth (6.2% CAGR) due to rising healthcare expenditure and infectious disease prevalence in countries like India and China.
Key Market DriversFactors such as increased awareness of early disease diagnosis, growing prevalence of infectious diseases, and demand for low-cost testing with accurate results are propelling the market. Personalized medicine initiatives and manufacturer promotional activities are further driving adoption.
Other TrendsApplication Areas
Infectious disease testing dominates (32% share), followed by pregnancy/fertility (18%) and glucose monitoring (15%). The oncology segment is projected to grow at 5.9% CAGR due to rising cancer screening programs.
Competitive LandscapeMajor players including Abbott, Roche Diagnostics, and Quidel Corporation hold 48% combined market share. Recent developments include mergers aimed at expanding test portfolios and geographic presence, particularly in emerging markets.
Regional Analysis: Rapid Tests MarketEurope
Europe represents the second-largest market for rapid tests, characterized by universal healthcare systems facilitating widespread test adoption. The region shows strong demand for infectious disease and pregnancy tests, with Germany and France leading in consumption. EU-wide standardization of diagnostic regulations creates a favorable business environment for manufacturers. Increasing focus on antimicrobial resistance monitoring drives specialized testing solutions. Decentralization of healthcare services in Nordic countries boosts point-of-care testing penetration.
Asia-Pacific
Asia-Pacific demonstrates the highest growth potential in the rapid tests market, fueled by improving healthcare access and rising health awareness. China and India emerge as key markets due to large population bases and increasing healthcare expenditures. Governments across the region actively promote rapid testing to combat infectious disease outbreaks. Local manufacturers gain market share through cost-effective products tailored to regional disease burdens. However, quality standardization remains a challenge in developing markets.
South America
South America's rapid tests market grows steadily, with Brazil and Argentina showing particularly strong demand. Public health initiatives emphasize rapid testing for vector-borne diseases prevalent in tropical regions. Economic constraints limit market expansion in some countries, though local production helps maintain affordability. Increasing private healthcare investments create opportunities for advanced diagnostic solutions in urban centers.
Middle East & Africa
The Middle East & Africa region shows uneven market development, with Gulf countries leading in adoption of premium rapid test solutions. Africa presents growth potential through public-private partnerships expanding access to essential diagnostics. Infectious disease prevalence creates sustained demand for malaria, HIV, and other rapid tests. Limited healthcare infrastructure in rural areas poses distribution challenges, though mobile testing initiatives help bridge gaps.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Diagnostic device manufacturers
Healthcare providers and clinics
Research institutions
Biotechnology companies
Investors and policy makers
-> Global rapid tests market was valued at USD 10.72 billion in 2024 and is projected to reach USD 14.74 billion by 2031.
Which key companies operate in Global Rapid Tests Market?
-> Key players include Abbott, Roche Diagnostics, Quidel Corporation, Becton Dickinson, and Bio-Rad Laboratories, among others.
-> Key growth drivers include increasing prevalence of infectious diseases, demand for decentralized diagnostics, and rising awareness of early disease detection.
-> North America held the largest market share, while Asia-Pacific is expected to witness the fastest growth.
-> Emerging trends include multiplex testing, smartphone-integrated testing solutions, and expansion of rapid testing for chronic diseases.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates